Pantimumab-Cancer Directed Fully Human Antibodies
Diyya Dias
Sneha Potdar
Abstract
The safety and efficacy of antibodies depends on their compatibility with the body system. Monoclonal antibodies having mouse sequences produce immunogenicity in humans, restricting their use. Genetically engineering transgenic mice with humanized humoral immune system is one of the possible solutions. They are obtained by merging human immunoglobulin loci with germ line of inactivated mouse antibody machinery. The hybrid mouse so obtained is called Xeno Mouse and is used as a source for high affinity high specificity human antibodies. Recently panitumumab (Vectibix) a completely human antibody directed against EGFR was successfully developed and approved in colorectal cancer treatment. This represents a milestone in the history and a herald for possible future applications of the Xeno Mouse technology.Downloads
Download data is not yet available.
